November 9, 2026
Five paths forward for resolving the federal debt.
The aluminum producer may not be what it once was, but there’s plenty of upside for investors.
Long Read
ResMed, whose devices treat sleep apnea, has dropped on unfounded concerns that weight-loss drugs will replace its treatment. The stock is cheap and worth buying at current prices.
Long Read
The Washington consensus is that Congress will be gridlocked for the rest of Trump’s presidency. Investors on Wall Street, however, see compromise on the horizon. Healthcare stocks, renewables, and more hang in the balance.
Long Read
The rout doesn’t mean run for the exits, but investors should choose semiconductor names wisely.
Long Read
The borrowing binge makes world markets even riskier and complicates the ability of central banks to step in to help. Where to ride out the storm.
Long Read
The success or failure of bot shoppers is going to come down to trust. So far, the retail establishment has the upper hand.
Long Read
Many of the hot new drug candidates in the U.S. were developed by Chinese companies.
Long Read
A host of business- and consumer-friendly policies could be on tap as newly empowered Democrats take control of Congress, writes Michael Hardaway.
Long Read
Jonathan Boyar, a principal in Boyar Value Group, says the firm tries “to buy the proverbial dollar for 50 cents.”
Long Read